Core Viewpoint - Mingyu Pharmaceutical is preparing for an IPO on the Hong Kong Stock Exchange, with a current valuation of approximately 3.936 billion yuan and a cumulative loss of 587 million yuan over two and a half years [1][2]. Company Overview - Founded in 2018, Mingyu Pharmaceutical is a biotechnology innovation company nearing commercialization, focusing on antibody-drug conjugates (ADC) and a novel PD-1/VEGF bispecific antibody [5]. - The company has a pipeline of 13 candidate products, with 10 in clinical stages, and aims to generate revenue from its autoimmune projects soon [5]. Product Pipeline - The core product MHB036C targets the TROP-2 ADC market, projected to grow from $1.5 billion in 2024 to $42.5 billion by 2035, with a CAGR of 35.4% [5]. - MHB088C is in Phase III trials for small cell lung cancer and has a partnership with Qilu Pharmaceutical worth 1.345 billion yuan [6]. - MHB018A is a first-in-class IGF-1R antibody in Phase III trials, showing strong potential [6]. - MH004 is a first-in-class JAK inhibitor for atopic dermatitis, with a new drug application submitted for 2025 [6]. Financial Performance - Revenue projections for 2023, 2024, and the first half of 2025 are 0 yuan, 0 yuan, and 264 million yuan, respectively, primarily from a licensing agreement with Qilu [7]. - R&D expenses for the same periods are 182 million yuan, 281 million yuan, and 98 million yuan, with net losses of 137 million yuan, 283 million yuan, and 167 million yuan [7]. Funding and Ownership - Mingyu Pharmaceutical has completed five rounds of financing, with the latest post-money valuation at approximately 3.936 billion yuan [10]. - The founder, Cao Guoqing, has extensive experience in drug research and development, having previously worked at Eli Lilly and Hengrui Medicine [10]. Intellectual Property - The company holds 23 issued patents and 107 patent applications, with a significant number related to its core products [7].

Core Viewpoint - Mingyu Pharmaceutical, founded by former Heng Rui executive Cao Guoqing, has officially submitted its IPO application to the Hong Kong Stock Exchange, focusing on oncology and autoimmune diseases, but has yet to achieve commercialization [1][3]. Financial Performance - The company reported no revenue for 2023 and 2024, with a revenue of 264.15 million RMB in the first half of 2025, primarily from a strategic partnership with Qilu Pharmaceutical [1][3]. - Cumulative losses reached 1.239 billion RMB by mid-2025, with net losses of 137.275 million RMB in 2023, 282.631 million RMB in 2024, and 167 million RMB in the first half of 2025 [2][3][4]. - Operating cash flow was negative for 2023 and 2024, at -143 million RMB and -146 million RMB respectively, turning positive to 102 million RMB in the first half of 2025 due to licensing fees from Qilu [4]. Research and Development - Mingyu Pharmaceutical has 13 candidate products in its pipeline, with 10 in clinical stages, but has not yet commercialized any products [3][5]. - The company plans to allocate 51% of its fundraising net proceeds to the development of two core products, MHB036C and MHB018A, with 26% for MHB036C and 25% for MHB018A [6]. Market Competition - The most advanced product, MH004, targets atopic dermatitis and has submitted a new drug application in China, facing competition from Heng Rui's products in a market projected to reach 14.9 billion USD in 2024 [5][6]. - The global market for atopic dermatitis drugs is expected to grow to 29.5 billion USD by 2035, indicating significant commercial potential [5]. Strategic Partnerships - The partnership with Qilu Pharmaceutical has been crucial for generating revenue, with a total transaction value of 1.345 billion RMB for rights in the Greater China region [3][4].

Core Insights - Mingyu Pharmaceutical has submitted its prospectus for an IPO, with joint sponsors including Morgan Stanley, Bank of America Securities, and CITIC Securities [1] - The company, founded in 2018 by former Hengrui executive Cao Guoqing, focuses on developing a robust pipeline of oncology products based on proprietary antibody-drug conjugate (ADC) platforms and a novel PD-1/VEGF bispecific antibody [1][2] - The company has 13 candidate products in its pipeline, with 10 in clinical stages, targeting oncology and autoimmune diseases [1] Product Pipeline - The core product MHB036C targets the TROP2 ADC market, valued at several billion dollars, and is currently in I/II phase trials for non-small cell lung cancer and II phase trials for breast cancer [2] - Another key product, MHB088C, is a potential best-in-class B7-H3 ADC for small cell lung cancer, currently undergoing III phase trials for second-line treatment [2] Financial Performance - The company has reported continuous net losses since its inception, with projected losses of RMB 1.373 billion, RMB 2.826 billion, and RMB 658 million for the years 2023, 2024, and the first half of 2025, respectively [4][6] - Revenue is expected to be approximately RMB 264 million in the first half of 2025, primarily from a licensing agreement with Qilu [3][4] Cash Flow and Financing - The company has consumed significant cash since its establishment, with net cash outflows from operating activities of RMB 1.43 billion, RMB 1.456 billion, and RMB 887 million for the years 2023, 2024, and the first half of 2024, respectively [9][11] - As of June 30, 2025, the company recorded net liabilities of RMB 12.862 billion and current liabilities of RMB 13.134 billion, indicating potential liquidity risks [10] Supplier Relationships - The company relies heavily on a few suppliers for its research and development activities, with the top five suppliers accounting for 49%, 58.6%, and 54% of total procurement in the respective years [8] Ownership Structure - Post-IPO, the company will not have a controlling shareholder, with the largest shareholder group holding approximately 36.27% of the voting rights [12]

Core Viewpoint - Minghui Pharmaceutical Co., Ltd. is positioned as a near-commercial biotechnology innovation company with dual growth engines, focusing on proprietary antibody-drug conjugate (ADC) platforms and a novel PD-1/VEGF bispecific antibody [2][4]. Pipeline Overview - As of November 16, 2025, Minghui has 13 candidate products in its pipeline, with 10 in clinical stages. The autoimmune projects are expected to generate revenue soon, while the oncology projects aim to innovate first-line cancer treatments through ADC monotherapy and combination therapies with PD-1/VEGF bispecific antibodies [3][4]. Key Products - The core product MHB036C targets the TROP-2 antigen for solid tumors and is in I/II phase trials for non-small cell lung cancer (NSCLC) and II phase trials for breast cancer. Another key product, MHB088C, is a B7-H3 ADC for small cell lung cancer (SCLC) and is currently in III phase trials [4][5]. Market Potential - The global ADC market is projected to grow from $13.5 billion in 2024 to over $216.3 billion by 2035, with a compound annual growth rate (CAGR) of 28.7%. The market for treatments of thyroid eye disease (TED) is expected to grow from $3.4 billion in 2024 to $13.4 billion by 2035, and the atopic dermatitis market is anticipated to expand from $14.9 billion to $29.5 billion in the same period [6]. Strategic Partnerships - Minghui has established a strategic collaboration with Qilu Pharmaceutical for MHB088C in Greater China, valued at 1.345 billion RMB. The clinical data for MHB088C has been selected for presentation at major oncology conferences, indicating strong interest from the medical community [7]. Funding and Valuation - Following the last round of financing in July, Minghui's valuation reached 3.936 billion RMB. The funds raised from the IPO will primarily support the development of core and key products, manufacturing, quality control, and commercialization capabilities [8].

Core Insights - Mingyu Pharmaceutical has submitted an application to the Hong Kong Stock Exchange, with joint sponsors including Morgan Stanley, Bank of America Securities, and CITIC Securities [1] - The company focuses on developing tumor therapies based on ADC platforms and PD-1/VEGF bispecific antibodies, as well as late-stage clinical assets for autoimmune diseases [1] Pipeline Overview - As of November 16, 2025, the company has 13 candidate products in its pipeline, with 10 already in clinical stages [1] - Key oncology products include MHB036C (TROP2ADC), which is in I/II phase studies for non-small cell lung cancer and breast cancer in combination with MHB039A (PD-1/VEGF bispecific antibody) [1] - Another significant oncology product, MHB088C (B7-H3ADC), is undergoing a Phase III monotherapy trial for small cell lung cancer and a Phase I/II combination trial with MHB039A [1] - Core autoimmune products include MHB018A (potential best-in-class IGF-1R antibody), currently in a Phase III trial for active thyroid eye disease (TED), and MH004 (first-in-class topical JAK inhibitor), which has submitted a new drug application in China for mild to moderate atopic dermatitis (AD) [1] Market Potential - According to Frost & Sullivan, the global TED market is expected to reach $13.4 billion by 2035, while the global atopic dermatitis treatment market is projected to reach $29.5 billion by 2035 [1] Technology Advantage - The company's proprietary SuperTopoi platform offers new ADC payloads that are 5-10 times more effective than the ADC based on Dxd, with superior safety profiles, including lower incidences of severe hematological toxicity and interstitial lung disease [2]

Company Overview - Mingyu Pharmaceutical Co., Ltd. has submitted its application to list on the Hong Kong Stock Exchange, with Morgan Stanley, BofA Securities, and CITIC Securities acting as joint sponsors [1] - Established in 2018, the company is a biotechnology innovation enterprise with a robust pipeline of clinical-stage oncology products and late-stage immunology assets [3][4] Product Pipeline - The company has 13 candidate products in its pipeline, with 10 currently in clinical stages, focusing on proprietary antibody-drug conjugates (ADCs) and a novel PD-1/VEGF bispecific antibody [3] - Key product MHB036C targets TROP 2 for solid tumors and is currently in I/II phase studies for non-small cell lung cancer (NSCLC) and breast cancer [3] - MHB088C is a potential best-in-class B7-H3 ADC for small cell lung cancer (SCLC), currently in III phase trials [4] - MHB018A is a first-in-class IGF-1R antibody for active thyroid eye disease (TED), also in III phase trials [4] - MH004 is a first-in-class topical JAK inhibitor for atopic dermatitis, with a new drug application submitted in 2025 [4] Market Potential - The global market for TED treatments is projected to grow from $3.4 billion in 2024 to $13.4 billion by 2035, with a CAGR of 13.2% [5] - The global market for atopic dermatitis treatments is expected to expand from $14.9 billion in 2024 to $29.5 billion by 2035, driven by increased adoption of targeted therapies in China [5] - The global pharmaceutical market is forecasted to grow from $1,333 billion in 2020 to $1,664 billion in 2024, with a CAGR of 5.7% [9] Financial Performance - The company reported revenues of approximately RMB 0 for the fiscal years 2023 and 2024, with projected revenue of RMB 264.15 million for the six months ending June 30, 2025 [6] - Losses for the fiscal years 2023, 2024, and the six months ending June 30, 2025, were approximately RMB 137.27 million, RMB 282.63 million, and RMB 167.01 million, respectively [7][8] Industry Trends - The global oncology drug market is expected to grow from $167 billion in 2020 to $262 billion in 2024, with a CAGR of 11.9% [9] - The ADC market is anticipated to experience explosive growth, projected to increase from $13.5 billion in 2024 to over $216.3 billion by 2035, with a CAGR of 28.7% [13] - China is expected to see a significant increase in its share of global oncology spending, with the oncology drug market projected to grow from $25.8 billion in 2020 to $37.2 billion in 2024 [10]

Company Overview - Mingyu Pharmaceutical Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with Morgan Stanley, BofA Securities, and CITIC Securities as joint sponsors [1] - Established in 2018, the company is a biotechnology innovation enterprise with a robust clinical-stage oncology product portfolio based on proprietary antibody-drug conjugate (ADC) platforms and a novel PD-1/VEGF bispecific antibody [3] - The company has 13 candidate products in its pipeline, with 10 in clinical stages, and aims to generate revenue from its autoimmune projects soon [3] Product Pipeline - The core product MHB036C targets the TROP 2 antigen for treating solid tumors and is currently in I/II phase studies for non-small cell lung cancer (NSCLC) and breast cancer [3] - Another key product, MHB088C, is a potential best-in-class B7-H3 ADC for small cell lung cancer (SCLC) and is undergoing a Phase III trial for second-line treatment [4] - The company’s proprietary SuperTopoi platform aims to address common issues in traditional ADC technology, offering payload efficacy 5 to 10 times that of existing ADCs while maintaining safety [5] Financial Performance - The company reported revenues of approximately 0 RMB for the fiscal years 2023 and 2024, with projected revenue of 264.15 million RMB for the six months ending June 30, 2025 [6] - Losses for the fiscal years 2023 and 2024 were approximately 137.27 million RMB and 282.63 million RMB, respectively, with a projected loss of 167.01 million RMB for the six months ending June 30, 2025 [7] Market Potential - The global market for TED (Thyroid Eye Disease) treatments is expected to grow from $3.4 billion in 2024 to $13.4 billion by 2035, with a CAGR of 13.2% [5] - The global market for atopic dermatitis treatments is projected to expand from $14.9 billion in 2024 to $29.5 billion by 2035, driven by increased adoption of targeted therapies in China [5] - The global pharmaceutical market is anticipated to grow from $1,333 billion in 2020 to $1,663 billion by 2024, with a CAGR of 5.7% [9] Industry Trends - The ADC market is expected to experience explosive growth, projected to increase from $13.5 billion in 2024 to over $216.3 billion by 2035, with a CAGR of 28.7% [13] - China is becoming a significant player in the global oncology drug market, with its market size expected to grow from $25.8 billion in 2020 to $37.2 billion by 2024, reflecting a CAGR of 9.6% [10] - The global oncology drug market is projected to grow from $167 billion in 2020 to $262.1 billion by 2024, with a CAGR of 11.9% [9]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Ming Yu Pharmaceutical Limited 明宇制药有限公司 (the ''Company'') (Incorporated in the Cayman Islands with limited liabilit ...

Ming Yu Pharmaceutical Limited 明宇製藥有限公司 （「本公司」） 香港聯合交易所有限公司及證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整性 亦不發表任何聲明，並表明概不就因本申請版本全部或任何部分內容而產生或依賴該等內容而引致的任何損 失承擔任何責任。 （於開曼群島註冊成立的有限公司） 的申請版本 警 告 本申請版本乃根據香港聯合交易所有限公司（「交易所」）及證券及期貨事務監察委員會（「證監會」）的要求而 刊發，僅用作向香港公眾人士提供資料。 本申請版本為草擬本，其所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即表示 閣下知 悉、接納並向本公司、其聯席保薦人、整體協調人、顧問及包銷團成員表示同意： 倘在適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據於香港公司註冊處處長登記的本公 司招股章程作出投資決定，其文本將於發售期內供公眾人士查閱。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的。投資者不應根據本文件所 載資料作出投資決定； (b) 在交易所網站登載本文件或其任何補充、修訂或更換附頁，並不會引致本公司、其聯 ...